From the view of an interventional cardiologist and a lipid medicine/atherosclerosis specialist, can you discuss what LDL-C thresholds vs. clinical burden/clinical history thresholds are important for patient selection for PCSK9-based risk reduction?

From the view of an interventional cardiologist and a lipid medicine/atherosclerosis specialist, can you discuss what LDL-C thresholds vs. clinical burden/clinical history thresholds are important for patient selection for PCSK9-based risk reduction?

Get Credit

From the view of an interventional cardiologist and a lipid medicine/atherosclerosis specialist, can you discuss what LDL-C thresholds vs. clinical burden/clinical history thresholds are important for patient selection for PCSK9-based risk reduction?

Created by

CMEducation Resources IQ&A Cardiovascular Intelligence Zone | The Interventional Cardiologist's Perspective

Presenter

Deepak Bhatt, MD, MPH, FACC, FAHA, FSCAI, FESC

Deepak Bhatt, MD, MPH, FACC, FAHA, FSCAI, FESC

Executive Director of Interventional Cardiovascular ProgramsBrigham and Women’s HospitalHeart and Vascular CenterProfessor of Medicine, Harvard Medical SchoolBoston, USA

Paul Ridker, MD

Paul Ridker, MD

Atherosclerosis Prevention Paul Ridker, MD, Eugene Braunwald Professor Harvard Medical School Division of Cardiovascular Medicine Director, Center for Cardiovascular Disease Prevention Brigham and Women’s Hospital Boston, MA